Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

New Zealand approves Thalidomide for multiple myeloma

Dec. 29, 2003

Target enrollment reached in ASCENT trial of DN-101

Dec. 29, 2003

Exelixis files IND for phase III trial of XL-119

Dec. 29, 2003

Esters of camptothecins with enhanced anticancer activity described in recent patent

Dec. 29, 2003

COX17 as a novel target for NSCLC

Dec. 23, 2003

Mitotic kinesin KSP inhibitors reported by Cytokinetics and GlaxoSmithKline

Dec. 23, 2003

Photobarr PDT recommended for approval in E.U.

Dec. 23, 2003

Array BioPharma and AstraZeneca to develop MEK program for oncology

Dec. 23, 2003

Alexion and XOMA collaborate on c-MPL agonist antibody development

Dec. 23, 2003

Highlights from the 2003 AACR-NCI-EORTC International Conference available on the LifeSci Channel

Dec. 23, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.